# Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants

> **NCT00673868** · PHASE1 · COMPLETED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** CMV Specific Cytotoxic T Lymphocytes

## Key facts

- **NCT ID:** NCT00673868
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-08-06
- **Final completion:** 2008-08-06
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673868, "Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00673868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*